‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
RSS SUMMARY · AGGREGATED FROM CNBC
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Continue Reading
The full story continues on CNBC.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
CNBC
US
Finland’s president says EU should expand to 40 states — including Canada
CNBC·2h ago·3 min read
US
Amazon engineers in Seattle slam employer for building AI data centers while laying off 30,000 staffers
CNBC·7h ago·3 min read
US
Elon Musk’s net worth poised to sail past $1 trillion in SpaceX IPO
CNBC·8h ago·3 min read
US
Broadcom stock slips on disappointing software revenue
CNBC·10h ago·3 min read
Related
On this beat
Health
An Uncertain Path for Americans Exposed to Ebola
TNYT·11h ago·3 min read
Health
Autism therapy has attracted predatory providers who bill for phantom services, pad hours and charge steep fees for care delivered by low-paid workers. Here are five takeaways from a WSJ investigation
TWSJ·15h ago·3 min read
Health
New research could help doctors tweak anesthesia to more resemble natural sleep, reducing risks
TWSJ·15h ago·3 min read
Health
Diets high in ultraprocessed foods are associated with an increased risk of dementia, a new study says, adding to the list of health problems linked to foods such as cookies, hot dogs and pizza
TWSJ·22h ago·3 min read